Compare ANDG & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDG | VKTX |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | 52300 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.4B |
| IPO Year | N/A | 2014 |
| Metric | ANDG | VKTX |
|---|---|---|
| Price | $42.82 | $34.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $31.17 | ★ $95.86 |
| AVG Volume (30 Days) | 392.5K | ★ 2.4M |
| Earning Date | 03-17-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.02 | N/A |
| Revenue Next Year | $13.67 | N/A |
| P/E Ratio | $44.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.12 | $22.96 |
| 52 Week High | $45.00 | $43.15 |
| Indicator | ANDG | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 44.70 |
| Support Level | $34.11 | $34.03 |
| Resistance Level | $45.00 | $36.77 |
| Average True Range (ATR) | 2.54 | 2.05 |
| MACD | 0.06 | -0.66 |
| Stochastic Oscillator | 78.17 | 3.75 |
Andersen Group Inc is a provider of independent tax, valuation, and financial advisory services to individuals and family offices, businesses, and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services. The firm generates the key revenue from Private Client Services, which provide comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving, and trust and estate planning.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.